Mutaflor (Escherichia Coli Strain Nissle 1917)

The Nissle 1917 strain colonises the gut lumen, competes with pathogenic microbes, strengthens the mucosal barrier, and modulates immune signalling. These actions collectively promote microbial equilibrium and dampen inflammatory pathways associated with ulcerative colitis.

The dosage regimen for Mutaflor is determined by the prescribing healthcare professional based on the patient’s condition, age, and clinical response. Patients should follow the specific instructions provided by their prescriber.

Safety data for Mutaflor in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the mother or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Mutaflor, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Unlike conventional anti‑inflammatory drugs, Mutaflor is a live probiotic that aims to restore microbial balance rather than directly suppress immune pathways. It is often used as an adjunct to standard therapy for maintenance of remission, whereas other agents such as mesalamine or biologics target inflammation more directly.

Mutaflor should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, and avoid exposure to direct sunlight to maintain bacterial viability.

Mutaflor is taken orally, typically as a capsule or sachet containing the live bacterial strain. It should be swallowed with water according to the prescriber’s instructions, and may be taken with or without food depending on the specific guidance provided.

Serious risks, though rare, include systemic infection such as bacteraemia or sepsis, particularly in immunocompromised individuals. Severe allergic reactions, including anaphylaxis, have also been reported. Patients should seek immediate medical attention if they experience fever, chills, or signs of infection.

Mutaflor is contraindicated in patients with known hypersensitivity to Escherichia coli Nissle 1917 or any excipients in the formulation. Caution is advised for severely immunocompromised patients, those with uncontrolled systemic infections, and individuals for whom safety in pregnancy or lactation has not been established.